Shukla Ajay Kumar, Atal Shubham, Banerjee Aditya, Jhaj Ratinder, Balakrishnan Sadasivam, Chugh Preeta Kaur, Xavier Denis, Faruqui Atiya, Singh Aakanksha, Raveendran Ramasamy, Mathaiyan Jayanthi, Gauthaman Jeevitha, Parmar Urwashi I, Tripathi Raakhi K, Kamat Sandhya K, Trivedi Niyati, Shah Prashant, Chauhan Janki, Dikshit Harihar, Mishra Hitesh, Kumar Rajiv, Badyal Dinesh Kumar, Sharma Monika, Singla Mamta, Medhi Bikash, Prakash Ajay, Joshi Rupa, Chatterjee Nabendu S, Cherian Jerin Jose, Kamboj Ved Prakash, Kshirsagar Nilima
Department of Pharmacology, All India Institute of Medical Sciences, Saket Nagar, Bhopal, Madhya Pradesh, 462020, India.
Department of Pharmacology, Vardhman Mahavir Medical College & Safdarjung Hospital, Near AIIMS Hospital, Ansari Nagar West, New Delhi, 110029, India.
Lancet Reg Health Southeast Asia. 2023 Mar;10:100129. doi: 10.1016/j.lansea.2022.100129. Epub 2022 Dec 13.
India has seen more than 43 million confirmed cases of COVID-19 as of April 2022, with a recovery rate of 98.8%, resulting in a large section of the population including the healthcare workers (HCWs), susceptible to develop post COVID sequelae. This study was carried out to assess the nature and prevalence of medical sequelae following COVID-19 infection, and risk factors, if any.
This was an observational, multicenter cross-sectional study conducted at eight tertiary care centers. The consenting participants were HCWs between 12 and 52 weeks post discharge after COVID-19 infection. Data on demographics, medical history, clinical features of COVID-19 and various symptoms of COVID sequelae was collected through specific questionnaire.
Mean age of the 679 eligible participants was 31.49 ± 9.54 years. The overall prevalence of COVID sequelae was 30.34%, with fatigue (11.5%) being the most common followed by insomnia (8.5%), difficulty in breathing during activity (6%) and pain in joints (5%). The odds of having any sequelae were significantly higher among participants who had moderate to severe COVID-19 (OR 6.51; 95% CI 3.46-12.23) and lower among males (OR 0.55; 95% CI 0.39-0.76). Besides these, other predictors for having sequelae were age (≥45 years), presence of any comorbidity (especially hypertension and asthma), category of HCW (non-doctors vs doctors) and hospitalisation due to COVID-19.
Approximately one-third of the participants experienced COVID sequelae. Severity of COVID illness, female gender, advanced age, co-morbidity were significant risk factors for COVID sequelae.
This work is a part of Indian Council for Medical Research (ICMR)- Rational Use of Medicines network. No additional financial support was received from ICMR to carry out the work, for study materials, medical writing, and APC.
截至2022年4月,印度新冠肺炎确诊病例已超过4300万例,康复率为98.8%,这使得包括医护人员在内的很大一部分人群容易出现新冠后遗症。本研究旨在评估新冠病毒感染后医学后遗症的性质和患病率,以及可能存在的风险因素。
这是一项在8个三级医疗中心进行的观察性多中心横断面研究。纳入的参与者为新冠病毒感染出院后12至52周的医护人员。通过特定问卷收集人口统计学、病史、新冠病毒感染的临床特征以及新冠后遗症的各种症状等数据。
679名符合条件的参与者的平均年龄为31.49±9.54岁。新冠后遗症的总体患病率为30.34%,其中疲劳(11.5%)最为常见,其次是失眠(8.5%)、活动时呼吸困难(6%)和关节疼痛(5%)。中度至重度新冠病毒感染的参与者出现任何后遗症的几率显著更高(比值比6.51;95%置信区间3.46 - 12.23),而男性出现后遗症的几率较低(比值比0.55;95%置信区间0.39 - 0.76)。除此之外,出现后遗症的其他预测因素包括年龄(≥45岁)、是否存在任何合并症(尤其是高血压和哮喘)、医护人员类别(非医生与医生)以及因新冠病毒感染住院治疗。
约三分之一的参与者出现了新冠后遗症。新冠疾病的严重程度、女性、高龄、合并症是新冠后遗症的重要风险因素。
本研究是印度医学研究理事会(ICMR)-合理用药网络的一部分。开展本研究工作、获取研究材料、进行医学撰写以及支付文章处理费均未获得ICMR的额外资金支持。